You must be aware that Telehealth has been growing absolutely huge in the last few years and that growth rate has been accelerated 10 folds by the rise of pandemic in 2020 and also the AI frenzy which is taking up the entire world by storm right now which means that people are trying to use the systems in ways that were never seen before. You must have seen the name of a telehealth company named Teladoc which has been doing well in the industry and providing remote support for doctors to check on their patients. Now, it is known that Teladoc is doing something that has never been done before in the industry. It is reported that Teladoc is using its tie-up with Microsoft to take advantage of AI and document patient visits using AI.
Teladoc says that they will be taking advantage of Microsoft’s “artificial intelligence services to automate clinical documentation on the telehealth platform” and it is also to be noted that OpenAI and Microsoft have a long-term partnership since the last few years and this is the reason why we see Microsoft’s products such as Bing and others getting ChatGPT and even GPT-4 integrated into their systems. It is also Microsoft who pushed Google to release their Bard AI as soon as possible so as to mitigate the risk of losing out visitors to Microsoft’s Bing search engine.
Talking about Teladoc and its vision, it is seen that the company will “use Microsoft’s Nuance Dragon Ambient eXperience, an AI-powered voice-enabled solution that uses the GPT4 AI service, to automatically document patient encounters for final review and signoff by clinicians. Teladoc’s CMO, in a statement, said “Administrative burden and staff shortages are major reasons why clinicians are leaving the profession”. At the moment, the exact details about how Teladoc is going to document visitors with AI is not known as the details are scarcely available but we will get to know the exact implementation in the coming days and we do hope that it will be beneficial to the telehealth industry, and healthcare, in general as well.